Abstract

Introduction: The measurement of C-reactive protein (CRP) to confirm the stability of COPD has been reported. However, CRP is a systemic inflammatory biomarker that is related to many other diseases. Objective: The objective of this study is to discover a diagnostic biomarker for COPD. Methods: Sixty-one subjects with COPD and 15 healthy controls (10 healthy non-smokers and 5 smokers) were recruited for a 1-year follow-up study. Data regarding the 1-year acute exacerbation frequency and changes in lung function were collected. CRP and the identified biomarkers were assessed in the validation COPD cohort patients and healthy subjects. Receiver operating characteristic values of CRP and the identified biomarkers were determined. A validation COPD cohort was used to reexamine the identified biomarker. Correlation of the biomarker with 1-year lung function decline was determined. Results: Proteoglycan 4 (PRG4) was identified as a biomarker in COPD. The serum concentrations of PRG4 in COPD Global initiative for chronic Obstructive Lung Disease (GOLD) stages 1+2 and 3+4 were 10.29 ng/mL and 13.20 ng/mL, respectively; 4.99 ng/mL for healthy controls (P2=0.91, P=0.013). Conclusion: PRG4 may be a biomarker for identification of severity in COPD. It was related to the 1-year forced vital capacity decline in COPD patients.

Original languageEnglish
Pages (from-to)1999-2007
Number of pages9
JournalInternational Journal of COPD
Volume10
Issue number1
DOIs
Publication statusPublished - Sep 18 2015

Fingerprint

Proteoglycans
Chronic Obstructive Pulmonary Disease
Biomarkers
C-Reactive Protein
Lung
Vital Capacity
ROC Curve
Healthy Volunteers

Keywords

  • C-reactive protein
  • Exacerbation
  • Inflammation
  • Lung function decline

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health
  • Health Policy

Cite this

Proteoglycan 4 is a diagnostic biomarker for COPD. / Lee, Kang Yun; Chuang, Hsiao Chi; Chen, Tzu Tao; Liu, Wen Te; Su, Chien-Ling; Feng, Po Hao; Chiang, Ling Ling; Bien, Mauo Ying; Ho, Shu Chuan.

In: International Journal of COPD, Vol. 10, No. 1, 18.09.2015, p. 1999-2007.

Research output: Contribution to journalArticle

@article{8e5c371500314accb511e2868d870a1e,
title = "Proteoglycan 4 is a diagnostic biomarker for COPD",
abstract = "Introduction: The measurement of C-reactive protein (CRP) to confirm the stability of COPD has been reported. However, CRP is a systemic inflammatory biomarker that is related to many other diseases. Objective: The objective of this study is to discover a diagnostic biomarker for COPD. Methods: Sixty-one subjects with COPD and 15 healthy controls (10 healthy non-smokers and 5 smokers) were recruited for a 1-year follow-up study. Data regarding the 1-year acute exacerbation frequency and changes in lung function were collected. CRP and the identified biomarkers were assessed in the validation COPD cohort patients and healthy subjects. Receiver operating characteristic values of CRP and the identified biomarkers were determined. A validation COPD cohort was used to reexamine the identified biomarker. Correlation of the biomarker with 1-year lung function decline was determined. Results: Proteoglycan 4 (PRG4) was identified as a biomarker in COPD. The serum concentrations of PRG4 in COPD Global initiative for chronic Obstructive Lung Disease (GOLD) stages 1+2 and 3+4 were 10.29 ng/mL and 13.20 ng/mL, respectively; 4.99 ng/mL for healthy controls (P2=0.91, P=0.013). Conclusion: PRG4 may be a biomarker for identification of severity in COPD. It was related to the 1-year forced vital capacity decline in COPD patients.",
keywords = "C-reactive protein, Exacerbation, Inflammation, Lung function decline",
author = "Lee, {Kang Yun} and Chuang, {Hsiao Chi} and Chen, {Tzu Tao} and Liu, {Wen Te} and Chien-Ling Su and Feng, {Po Hao} and Chiang, {Ling Ling} and Bien, {Mauo Ying} and Ho, {Shu Chuan}",
year = "2015",
month = "9",
day = "18",
doi = "10.2147/COPD.S90926",
language = "English",
volume = "10",
pages = "1999--2007",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Proteoglycan 4 is a diagnostic biomarker for COPD

AU - Lee, Kang Yun

AU - Chuang, Hsiao Chi

AU - Chen, Tzu Tao

AU - Liu, Wen Te

AU - Su, Chien-Ling

AU - Feng, Po Hao

AU - Chiang, Ling Ling

AU - Bien, Mauo Ying

AU - Ho, Shu Chuan

PY - 2015/9/18

Y1 - 2015/9/18

N2 - Introduction: The measurement of C-reactive protein (CRP) to confirm the stability of COPD has been reported. However, CRP is a systemic inflammatory biomarker that is related to many other diseases. Objective: The objective of this study is to discover a diagnostic biomarker for COPD. Methods: Sixty-one subjects with COPD and 15 healthy controls (10 healthy non-smokers and 5 smokers) were recruited for a 1-year follow-up study. Data regarding the 1-year acute exacerbation frequency and changes in lung function were collected. CRP and the identified biomarkers were assessed in the validation COPD cohort patients and healthy subjects. Receiver operating characteristic values of CRP and the identified biomarkers were determined. A validation COPD cohort was used to reexamine the identified biomarker. Correlation of the biomarker with 1-year lung function decline was determined. Results: Proteoglycan 4 (PRG4) was identified as a biomarker in COPD. The serum concentrations of PRG4 in COPD Global initiative for chronic Obstructive Lung Disease (GOLD) stages 1+2 and 3+4 were 10.29 ng/mL and 13.20 ng/mL, respectively; 4.99 ng/mL for healthy controls (P2=0.91, P=0.013). Conclusion: PRG4 may be a biomarker for identification of severity in COPD. It was related to the 1-year forced vital capacity decline in COPD patients.

AB - Introduction: The measurement of C-reactive protein (CRP) to confirm the stability of COPD has been reported. However, CRP is a systemic inflammatory biomarker that is related to many other diseases. Objective: The objective of this study is to discover a diagnostic biomarker for COPD. Methods: Sixty-one subjects with COPD and 15 healthy controls (10 healthy non-smokers and 5 smokers) were recruited for a 1-year follow-up study. Data regarding the 1-year acute exacerbation frequency and changes in lung function were collected. CRP and the identified biomarkers were assessed in the validation COPD cohort patients and healthy subjects. Receiver operating characteristic values of CRP and the identified biomarkers were determined. A validation COPD cohort was used to reexamine the identified biomarker. Correlation of the biomarker with 1-year lung function decline was determined. Results: Proteoglycan 4 (PRG4) was identified as a biomarker in COPD. The serum concentrations of PRG4 in COPD Global initiative for chronic Obstructive Lung Disease (GOLD) stages 1+2 and 3+4 were 10.29 ng/mL and 13.20 ng/mL, respectively; 4.99 ng/mL for healthy controls (P2=0.91, P=0.013). Conclusion: PRG4 may be a biomarker for identification of severity in COPD. It was related to the 1-year forced vital capacity decline in COPD patients.

KW - C-reactive protein

KW - Exacerbation

KW - Inflammation

KW - Lung function decline

UR - http://www.scopus.com/inward/record.url?scp=84942333241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942333241&partnerID=8YFLogxK

U2 - 10.2147/COPD.S90926

DO - 10.2147/COPD.S90926

M3 - Article

C2 - 26451097

AN - SCOPUS:84942333241

VL - 10

SP - 1999

EP - 2007

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

IS - 1

ER -